Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has disclosed the signing of a pharmaceutical contract manufacturing agreement with a US-based pharmaceutical company valued at approx. KRW 1.800 trillion (USD 1,294,637,000), representing 39.59% of its FY2024 consolidated revenue.
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Title: Single Sales and Supply Contract
- Contract Classification & Title: Other Sales/Supply Contract (Pharmaceutical Contract Manufacturing Agreement)
- Contract Details:
- Contract Amount: KRW 1,800,063,284,800 (USD 1,294,637,000, applied exchange rate KRW 1,390.40 per USD on September 9, 2025)
- Recent Annual Revenue: KRW 4,547,322,176,421 (Based on FY2024 consolidated financial statements)
- Contract Amount to Revenue Ratio: 39.59%
- Counterparty: Pharmaceutical company based in the United States
- Contract Period: August 29, 2025 – December 31, 2029
- Contract Date: September 9, 2025
- Disclosure Postponement Details:
- Reason for Postponement: Business confidentiality
- Postponement Expiration & Counterparty Disclosure Date: December 31, 2029 (Subject to change)
- Other Important Details:
- The contract end date is subject to change upon mutual agreement.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Contract Execution and Subsequent Official Disclosures
This disclosure provides notice of a major contract manufacturing deal with a US-based pharmaceutical company, equivalent to 39.59% of the company’s recent annual revenue.
Monitoring potential updates to the contract amount and period, as well as tracking official announcements aligned with the confidentiality postponement date (December 31, 2029), is essential.
Relevant developments can be verified in future correction disclosures, periodic filings, and official disclosures upon expiration of the postponement period.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
